#fda

Wockhardt Stock Surges 19% Amid FDA Approval for Novel Antibiotic Wockhardt's stock price surged 19% on Monday, hitting an all-time high of ₹2,420 on the BSE, following the company's announcement of U.S. Food and Drug Administration (FDA) approval for Zaynich, a novel intravenous antibiotic. The stock also rallied 75% over the past month, outperforming the BSE Sensex's 3% decline. The approval, which came after a significant rise in trading volumes, marks a pivotal moment for the pharmaceutical company, positioning it as a leader in the fight against antimicrobial resistance. Zaynich, a combination of cefepime and zidebactam, is designed to treat complicated urinary tract infections (cUTIs), including pyelonephritis, in adults. The drug targets a critical market, as over 2.8 million antimicrobial-resistant infections occur annually in the U.S., causing more than 35,000 deaths. cUTIs alone account for over 600,000 hospitalizations each year, underscoring the drug's potential to address a significant unmet medical need. The FDA's approval is expected to unlock a $9 billion market opportunity in the U.S. alone, with ICICI Securities highlighting its transformative impact on Wockhardt's profitability. The approval of Zaynich is particularly notable as it represents the first new chemical entity (NCE) fully developed and commercialized by an Indian pharmaceutical company to receive U.S. FDA approval. Wockhardt's pipeline includes six antibiotics in various stages of development, with three targeting Gram-Negative pathogens and three targeting Gram-Positive bacteria. All six drugs have been granted Qualified Infectious Disease Product (QIDP) designation by the FDA, accelerating their development and enhancing their commercial prospects. Wockhardt's financial performance has also strengthened, with the company reporting a 12.#fda #icici_securities #ockhardt #zaynich #icra

FDA Approval Positions Wockhardt's Zaynich in $9 Billion Antibiotics Market Wockhardt, an Indian pharmaceutical company, has secured U.S. Food and Drug Administration (FDA) approval for its novel antibiotic, Zaynich. The drug targets drug-resistant bacteria, specifically superbugs that evade conventional treatments. Its unique mechanism of action, termed the beta-lactam enhancer approach, offers a significant breakthrough in combating antimicrobial resistance (AMR). The approval positions Zaynich in a $9 billion market opportunity, with Wockhardt anticipating market exclusivity in the U.S. until approximately 2038. The drug’s development began in 2011 when Wockhardt’s medicinal chemistry team successfully synthesized zidebactam, the active ingredient in Zaynich. This compound works by inhibiting two sequential steps in bacterial cell wall synthesis, creating a synergistic effect that overcomes resistance mechanisms. Unlike traditional beta-lactamase inhibitors, which target enzymes that destroy beta-lactam antibiotics, zidebactam focuses on complementary binding to penicillin-binding proteins (PBPs), specifically PBP2 and PBP3. This dual inhibition leads to rapid bacterial cell death, regardless of the beta-lactamase enzymes present. Wockhardt’s journey to FDA approval faced several challenges. The company filed its Investigational New Drug (IND) application in 2014-15 and completed Phase I studies, which impressed regulators enough to grant a waiver for Phase II efficacy trials. This allowed direct progression to Phase III. A major setback occurred with the outbreak of the Russia-Ukraine war, which disrupted clinical trials in Ukraine. Wockhardt had to relocate sites to Eastern Europe, India, and China, delaying the program by nearly a year. The U.S.#fda #ockhardt #zaynich #beta_lactam #amr

Metal Fragments Found in Organic Ice Cream Sold in Connecticut, FDA Warns Straus Family Creamery has issued a voluntary recall for certain flavors of organic ice cream distributed in Connecticut and 16 other states due to the potential presence of metal foreign material. The company announced the recall on Thursday, stating it is removing a limited number of production runs of select flavors and sizes from store shelves. The affected lots were shipped to 17 states, including Connecticut, New Jersey, and Pennsylvania. The U.S. Food and Drug Administration has been notified of the recall, and the company is working with retailers to remove the potentially impacted products. Straus Family Creamery emphasized that food safety and product quality remain its top priorities, noting the action was taken out of an abundance of caution. The company has implemented corrective measures to address the issue. No injuries related to the potential contamination have been reported. The recall does not apply to all Straus ice cream products. The following flavors and sizes are included in the recall: Vanilla Bean, pint – best-by dates of December 23, 2026, and December 28, 2026 Strawberry, quart – best-by date of December 24, 2026 Strawberry, pint – best-by date of December 25, 2026 Cookie Dough, pint – best-by date of December 26, 2026 Dutch Chocolate, quart – best-by date of December 27, 2026 Mint Chip, pint – best-by date of December 30, 2026 The best-by dates are printed on the bottom of the containers. Consumers are urged not to consume the recalled products and instead discard them. Returning the items to stores is discouraged. Customers who purchased the affected products can obtain a replacement voucher by completing a form on the company’s website at www.strausfamilycreamery.com/recall/#form.#fda #connecticut #shoprite #straus_family_creamery #whole_foods_markets

Supreme Court Allows Telehealth and Mail Access to Mifepristone for Now The U.S. Supreme Court on Thursday temporarily upheld the availability of the abortion pill mifepristone through telehealth visits, preserving access for women while Louisiana’s legal challenge to its distribution continues in lower courts. The decision, issued nearly an hour after an earlier administrative stay on the drug’s access expired, paused a May 1 ruling by the 5th U.S. Circuit Court of Appeals that had mandated in-person visits for the medication. The high court’s order did not specify its reasoning or disclose the vote count, though Justices Clarence Thomas and Samuel Alito issued dissents. The ruling comes amid a contentious legal battle over mifepristone, a drug used in medication abortions, which has become central to abortion rights debates since the Supreme Court overturned Roe v. Wade in 2022. Louisiana, a conservative state with a strict abortion ban, filed a lawsuit against the Food and Drug Administration (FDA) over its 2023 policy allowing telehealth access to mifepristone. The state argued the regulation undermined its laws and posed risks to public health. A federal district court in April partially supported Louisiana’s claim, ruling the FDA’s policy arbitrary due to insufficient safety data, but blocked its immediate enforcement to allow the agency time to review the drug. The 5th Circuit Court of Appeals then issued an emergency stay in late April, requiring in-person visits for mifepristone, which triggered widespread chaos among medical providers and patients. The Supreme Court’s intervention halted that order, returning the case to the 5th Circuit for further review.#fda #supreme_court #louisiana #5th_circuit_court_of_appeals #mifepristone

FDA Unveils Results of Largest-Ever Infant Formula Safety Study The U.S. Food and Drug Administration announced on April 29, 2026, the findings of its most extensive examination to date of chemical contaminants in infant formula sold across the country. The agency emphasized that while breast milk remains the ideal nutritional source for infants, millions of parents rely on formula, and the results of this comprehensive testing underscore the importance of maintaining strict safety standards. Health and Human Services Secretary Robert F. Kennedy, Jr., highlighted that the study involved testing more than 300 infant formula samples, representing a wide range of products available at retail locations nationwide. These samples were analyzed for over 120,000 data points, covering contaminants such as lead, mercury, cadmium, arsenic, pesticides (including glyphosate and glufosinate), per- and polyfluoroalkyl substances (PFAS), and phthalates. The testing included powders, ready-to-feed liquids, and concentrated liquids, all rigorously evaluated in FDA laboratories. Kennedy stated, “We tested more infant formula than ever before, and the results are clear: most products meet a high safety standard—but even small exposures matter for newborns.” He reiterated the agency’s commitment to holding manufacturers accountable and providing parents with transparent, reliable information to ensure the safety of their children. FDA Commissioner Marty Makary, M.D., M.P.H., added that the findings were encouraging, noting that an overwhelming majority of samples had undetectable or very low levels of contaminants. He emphasized the agency’s ongoing efforts to advance formula innovation and safety, stating, “The results of this study are encouraging.#fda #marty_makary #robert_f_kennedy #kyle_diamantas #operation_stork_speed

Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib showed clinical benefit in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors carried a KRAS G12C mutation and had progressed after prior therapies, according to findings presented at the American Association for Cancer Research (AACR) Annual Meeting 2026. The study, led by Byoung Chul Cho, MD, Ph.D., a professor at Yonsei University College of Medicine, highlighted the drug’s potential to address limitations of earlier treatments. The KRAS G12C mutation is the most common alteration in NSCLC, and two first-generation inhibitors—sotorasib (Lumakras) and adagrasib (Krazati)—have been approved by the U.S. Food and Drug Administration (FDA) for this patient group. However, these drugs only benefit about 30% of patients, with half experiencing disease progression within six months. Safety concerns also persist, prompting research into next-generation inhibitors like elisrasib. Elisrasib works by selectively binding to the mutant KRAS G12C protein, locking it in an inactive state to block its oncogenic activity. Unlike earlier inhibitors, elisrasib was designed for faster and stronger target engagement, potentially leading to sustained inhibition. The drug is currently being tested in an ongoing phase I/II trial for KRAS G12C-mutant solid tumors, with early data from a subgroup of NSCLC patients showing encouraging results. In patients who had not previously received KRAS G12C inhibitor therapy (naive), the median follow-up was 11.3 months, while those with prior resistance had a median follow-up of 10.6 months.#fda #american_association_for_cancer_research #yonsei_university_college_of_medicine #kras_g12c #elisrasib

Immunoterapia GLSI-100 w leczeniu raka piersi – wyniki badania FLAMINGO-01 Wstępne wyniki badania FLAMINGO-01 wskazują, że szczepionka przeciwnowotworowa GLSI-100 może stać się istotnym elementem leczenia uzupełniającego pacjentek z HER2-dodatnim rakiem piersi, które ponownie zachorują po standardowym leczeniu okołooperacyjnym. Badanie, prowadzone w ramach III fazy klinicznej, ocenia skuteczność nowej terapii immunologicznej w grupie chorych z wysokim ryzykiem progresji choroby. Rak piersi z nadekspresją receptora HER2 to agresywny podtyp nowotworu, który w przeszłości wiązał się z wysokim ryzykiem nawrotu. Wprowadzenie terapii ukierunkowanych molekularnie, takich jak trastuzumab, znacząco poprawiło rokowanie pacjentek. Jednak u części chorych, zwłaszcza z obecnością choroby resztkowej po leczeniu neoadjuwantowym, ryzyko nawrotu pozostaje wysokie. W związku z tym badacze poszukiwali nowych strategii terapeutycznych, w tym podejść immunologicznych, które mogłyby zmniejszyć ryzyko progresji. GLSI-100 to szczepionka oparta na peptydzie HER2/neu (GP2) w połączeniu z czynnikiem stymulującym tworzenie kolonii granulocytów i makrofagów (GM-CSF). Mechanizm działania polega na indukcji swoistej odpowiedzi immunologicznej przeciwko komórkom nowotworowym ekspresyjnym HER2. Badanie FLAMINGO-01 jest prospektywnym, randomizowanym, podwójnie zaślepionym badaniem klinicznym z grupą kontrolną placebo, prowadzonym wieloośrodkowo. Do udziału kwalifikowani są pacjenci z HER2-dodatnim rakiem piersi w stopniu zaawansowania od I do III, którzy ukończyli leczenie okołooperacyjne obejmujące terapię neoadjuwantową i leczenie uzupełniające oparte na trastuzumabie. W analizie otwartej części badania, obejmującej pacjentów z ujemnym allelem HLA-A02, wykazano bardzo niski odsetek nawrotów choroby.#fda #her2_dodatni_rak_piersi #flamingo_01 #glsi_100 #hlA_a02

2026 ‘Dirty Dozen’ Produce: Nearly 100% Tested Positive for Pesticides, Including ‘Forever Chemicals’ Researchers have identified the most pesticide-contaminated fruits and vegetables in the 2026 Shopper’s Guide to Pesticides in Produce, highlighting concerns about harmful residues in commonly consumed items. Leafy greens like spinach and popular foods such as strawberries and grapes topped the list, with spinach showing the highest levels of pesticide residue by weight. The Environmental Working Group (EWG) released the report, which analyzed data from USDA tests on 54,344 samples of 47 fruits and vegetables. The “Dirty Dozen” list includes nectarines, peaches, cherries, apples, blackberries, pears, potatoes, and blueberries. Spinach, which ranked first, averaged four or more pesticide types, while potatoes had the lowest average at two. Experts warn that exposure to multiple pesticides may increase health risks, as residues can accumulate over time. The USDA’s testing process involved peeling, scrubbing, and washing produce to simulate home preparation, yet traces of 264 pesticides were found, with 203 linked to the Dirty Dozen. Pesticides have been associated with various health issues, including premature births, congenital malformations, heart disease, cancer, and developmental problems in children. The American Academy of Pediatrics notes that pesticide exposure during pregnancy or childhood can lead to birth defects, low birth weight, and attention or learning difficulties. The report also revealed that over 60% of Dirty Dozen samples contained PFAS, or “forever chemicals,” which are persistent in the environment and linked to cancer, obesity, thyroid disease, and immune system damage.#fda #environmental_working_group #american_academy_of_pediatrics #alliance_for_food_and_farming #croplife_america

Novo Nordisk's U.S. headquarters faces FDA scrutiny in latest regulatory action Novo Nordisk’s U.S. headquarters in Plainsboro, New Jersey, has been issued a formal FDA warning letter following an inspection that uncovered compliance issues related to postmarketing adverse drug experience (PADE) reporting. The agency’s findings, detailed in the letter, highlight gaps in the company’s procedures for tracking and reporting side effects of its medications, including Ozempic and Wegovy. Novo acknowledged the letter in a public statement, emphasizing its commitment to addressing the concerns and resolving the issues with the FDA. The FDA’s inspection of the Plainsboro site, which serves as Novo’s U.S. operations hub, took place from January 13 to February 7, 2025, as part of a review of the company’s adherence to PADE regulations. During the inspection, the agency identified multiple shortcomings in Novo’s processes for monitoring and reporting adverse events. These included delays in submitting reports to the FDA, the ability to reject or cancel received reports, and insufficient medical review timelines for evaluating adverse events. The FDA also criticized Novo for failing to thoroughly investigate the root causes of these issues, raising concerns about the company’s ability to ensure product safety. In response, Novo stated it has implemented corrective and preventive action plans and has submitted seven updates to the FDA since the initial Form 483 notice was issued on February 7, 2025. The company argued that the warning letter primarily seeks additional details to confirm its compliance efforts and does not reflect any assessment of the quality or safety of its drugs. Anna Windle, head of clinical development at Novo Nordisk U.S.#fda #novonordisk #ozempic #wegovy #plainsboro_new_jersey

FDA Warns Novo Nordisk of Unreported GLP-1 Side Effects The U.S. Food and Drug Administration has sent a warning letter to Novo Nordisk, the Danish pharmaceutical company that produces the weight-loss drugs Ozempic and Wegovy, accusing the firm of failing to report potential side effects linked to its medications. The agency highlighted three patient deaths associated with the drugs, including one case involving a suicide, and stated that Novo Nordisk did not disclose these incidents within the required timeframe. The FDA also criticized the company for not conducting a thorough investigation into the suicide and for not reporting the event to the agency. The warning letter, dated March 11, 2026, underscores concerns about the safety profile of GLP-1 receptor agonists, a class of drugs used to treat type 2 diabetes and obesity. While these medications have been widely prescribed for their effectiveness in weight management, the FDA’s actions highlight growing scrutiny over their long-term risks. The agency emphasized that Novo Nordisk’s failure to comply with reporting requirements could jeopardize patient safety and regulatory oversight. The deaths cited in the warning include a patient who died by suicide, though the FDA did not specify the exact circumstances of the incident. The agency’s statement suggests that the company’s lack of transparency may have contributed to a delayed response to potential safety issues. This comes amid ongoing debates about the broader use of GLP-1 drugs, which have faced criticism for their high cost and potential side effects, including gastrointestinal distress, cardiovascular risks, and mental health concerns. Novo Nordisk, a global leader in diabetes care, has faced increasing pressure from regulators and healthcare professionals to address safety concerns.#fda #novonordisk #ozempic #wegovy #glp_1_receptor_agonists

The provided text includes a mix of news snippets and unrelated content. Here's a concise summary of the key points: Medical Contract Approval: A medical contract was approved for Colbert County jail, likely related to healthcare services or inmate care. Distracted Driving: A section on distracted driving highlights its risks and potential regulatory or safety measures. FDA Hiring: A top FDA drug official is attempting to hire a friend, raising questions about conflicts of interest or regulatory oversight. Aging Dogs & Supplements: Pup Labs is developing targeted supplements to support aging dogs, addressing joint stiffness and mobility issues. Travel Trends: Wellness-focused travel trends are redefining the industry, emphasizing health, relaxation, and personalized experiences. The repeated "word" entries at the end appear to be formatting errors or placeholders and are not part of the main content. Let me know if you need further clarification!#colbert_county_jail #pup_labs #fda #distracted_driving #wellness_travel